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A. R. Bird, B. J. Gibbs
Transmission of hepatitis viruses has been recognised as an
undesirable effect of blood transfusion since the 1940s,
when large outbreaks occurred following inoculation with a
yellow fever vaccine which contained pooled human plasma.
Further reports followed of jaundice occurring several
months after transfusions with blood or plasma.' It was also
noted in studies in the UK that the incidence of icteric
hepatitis increased relative to the number of units
transfused!
After the discovery of the Australia antigen in 1965, its
recognition as a marker of hepatitis B virus (HBV) infection
and its association with post-transfusion hepatitis (PTH), the
subsequent introduction of screening tests for this antigen in
the early 1970s led to a marked decrease in the incidence of
PTH_ However, despite increasingly sensitive testing
methods for hepatitis B surface antigen (HBsAg), as it
subsequently became designated, viral hepatitis was still
considered the commonest lethal complication of blood
transfusion.' It was clear that there were still a number of
cases of PTH that were due neither to hepatitis A virus nor
to HBV, and the term 'non-A, non-B hepatitis' (NANBH) was
coined.
The introduction of molecular techniques enabled clones
to be derived·from the genome of an agent associated with
transfusion-transmitted NANBH,3 and the proteins derived
from these clones were then used to develop nn enzyme-
linked immunosorbent assay (ELlSA)' to detect antibodies to
this virus, now termed hepatitis C virus (HCV). This ELlSA is
now used in most developed countries to screen for HCV
antibodies.
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Current status of hepatitis
testing
HBV
All transfusion services in South Africa currently screen for
HBsAg with ELlSA kits. These tests have a high sensitivity
and specificity, but it is well recognised that current methods
for HBsAg detection are not yet sensitive enough to detect
all potentially infectious units of blood or possible cases of
hepatitis, although the risk of PTH is still very low.
For this reason the transfusion services also have
stringent exclusion criteria and all persons with a history of
hepatitis after the age of 10 - 12 years are either
permanently excluded from donation or deferred for 12
months after recovering from the illness. Also, all donors
who have had contact with a person suffering from hepatitis
are excluded from donation for 6 months.
Should a donor sample be found reactive for HBsAg, a
confirmatory test with a neutralisation technique is
performed. If this is positive the donor is considered HBsAg
positive and the unit is discarded. The donor is then
informed by letter of the result of the test and advised to
consult a physician.
The overall prevalence of HBsAg among apparently
healthy donors in South Africa is currently approximately
0,5%, although this ranges from approximately 0,1% in
white donors to 4 - 5% in black donors. New donors also
have a higher prevalence than regular donors.
The prevalence of transfusion-related HBV infections is
not known since a proper prospective study would be
required. However, in the Western Cape we are aware of
only 3 cases of proven transfusion-transmitted HBV
infections during the past decade. In the context of the
infusion of approximately 150 000 blood component
transfusions each year in the Western Cape, the risk of
HBV infection from transfusion remains very low.
HCV
Despite the introduction of HBsAg tests, cases of PTH
continued to occur; in the USA the incidence was as high as
10% in the early 1980s,' although it varied widely in different
parts of the world and clearly was also related directly to the
number of units infused. The true extent of PTH in a given
population can only be measured by careful follow-up of
transfused recipients over several months. This is because
the vast majority of cases of PTH (particularly NANBH) are
asymptomatic and initially can only be detected by the serial
measurement of liver enzyme levels, especially alanine
aminotransferase (ALT), in the recipient following transfusion.
In the absence of a specific test, blood transfusion
services in the USA and in some European countries began
screening donations for surrogate markers of NANBH,
namely elevated levels of ALT and for antibodies to HBV
core antigen (anti-HBc). Based on a retrospective analysis
from a study of blood donors and patients with PTH at the
National Institute of Health, a reduction of 30 - 50% was
predicted for the incidence of NANBH following introduction
of surrogate testing, but no prospective evaluation was
conducted.' However, a decline in PTH in the USA was
noted before the introduction of surrogate marker tests for
NANBH, and was probably due to stricter donor selection
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and screening procedures introduced to prevent HIV
transmission.' Although some countries, including the USA,
have continued to screen for anti-HBc and ALT levels, there
remains some controversy whether this is truly efficacious
and cost-effective in the light of improved anti-HCV tests.
Anti-HBc tests may also be useful in identifying units
infectious for HBV with sub-detectable levels of HBsAg,
especially precore-defective HBV mutants.' However, in
countries of high endemicity for HBV (such as South Africa)
where many donors may be positive for anti-HBc, it would
be difficult to discard all anti-HBc positive units because this
would strain the blood resources. A survey of 300 donors in
Natal in 1987 revealed anti-HBc-positive rates ranging from
approximately 4% in whites to approximately 30% in black
donors (C. Prior - unpublished data).
With the cloning of nucleic acid sequences from an RNA
virus putatively responsible for most NANBH infections and
the development of an assay for anti-HCV,3A screening for
anti-HCV is now routine in most countries and is part of the
screening process in all blood transfusion services in South
Africa. The first-generation tests had rather poor positive
predictivity values for HCV infection in populations with a
low prevalence of HCV. Although the second-generation
tests are an improvement, specificity remains a problem,
with a relatively large number of false positives in low
prevalence populations. However, as the tests are refined,
fewer false positives are likely.
Anti-HCV screening is also very expensive and this has
certainly affected its introduction in developing countries.
Modifications such as pooling samples to decrease costs
have been proposed, with apparently satisfactory results
among Egyptian donors using Abbott second-generation
assays" but we have been unable to reproduce their results
using the same test system (A. Bird, B. Gibbs -
unpublished data). However, other test systems may yield
more satisfactory results and are currently being evaluated
in this respect. An alternative cost-saving approach is to
screen out the donor base initially and then repeat anti-HCV
testing on a rotational basis on repeat donations (e.g. every
third - fifth donation), since it has been shown that HCV
seroconversion rates in donors are extremely low (J.
Barbara, P. Coghlan - personal communication).
The donor population in South Africa has a relatively low
prevalence of HCV positivity at approximately 0,3 - 0,4%
although, as in HBV infection, there are geographical and
racial differences in prevalence. These figures are
comparable to the prevalence of < 1% in most developed
countries, with the exception of Japan where HCV
prevalence among donors is around 1 - 2% and where PTH
was common prior to HCV screening.' Risk factors for HCV
. infection among anti-HCV positive donors followed up in the
Western Cape are not clearly established, with more than
50% of infected donors having no apparent source of
infection. This is in contrast to studies in the USA where
approXimately 40% of infections are associated with
intravenous drug abuse.'Q
There has been only one prospective study of PTH in
South Africa of which we are aware, in which 68
cardiothoracic surgery patients who received on average 6
red cell units each were followed up." Only 1 patient (1,4%)
contracted NANBH based on serial measurements of ALT.
With the advent of anti-HCV screening, one would predict
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that the current prevalence of PTH would be well below this
rate. Indeed, based on the USA experience, the current risk
for PTH is approximately 3 per 10 000 units transfused6 and
since we have similar prevalence rates among our donors, it
is likely that the risk in South Africa is similar. It is also
important to bear in mind that recent studies with long-term
follow-up indicate that post-transfusion HCV infection has a
negligible effect on morbidity and mortality.'2
The current practice therefore is to screen all donors for
HCV antibodies. Should the test be repeatedly reactive, the
unit will be discarded and the donor informed by letter of the
results and advised to consult a physician for further testing
and clinical follow-up. Should further clinical and laboratory
follow-up suggest a false positive result we would accept
the donor back, but only if the screening test and currently
available confirmatory tests are non-reactive 6 months after
the initial screen. However, as indicated in the article by
Voigt and Smuts in this issue (pp 535-548), confirmatory
testing is a problem and ideally all donors with positive tests
should be confirmed as truly infected by sensitive viral
detection methods such as polymerase chain reaction (PCR)
techniques. This is relatively time-consuming and expensive,
but recent sensitive recombinant immunoblot assays (RIBAs)
appear to correlate reasonably well with PCR technology,
particularly if the antibodies show reactivity with either C33C
and C22 antigens." Reactivity with C100 and/or 5-1-1
antigens correlates poorly with PCR positivity and is
regarded as indeterminate."
Clearly, the present anti-HCV tests are still overly sensitive
and not sufficiently specific in terms of diagnosing individual
patients. Nevertheless, in the context of screening blood
donors, erring on the side of sensitivity is preferable.
Unfortunately this leads to the unnecessary exclusion of
some donors and uncertainty as to whether some are truly
infected. This must, however, be balanced against the
maintainance of a safe blood supply and the likelihood that
more specific, yet sensitive, tests .for HCV infection will be
developed during the next few years.
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Liver transplantation for
viral hepatitis - which
patients will benefit?
D. Kahn, C. W. Spearman, A. J. W. Millar
Liver transplantation constitutes a significant part of the
hepatologist's armamentarium and has become the
treatment of choice for most patients with chronic end-stage
liver disease. The results continue to improve and many
centres are now able to achieve 1-year survival figures in
excess of 90% in selected patients. The surgical techiques
involved in liver transplantation and the immunosuppressive
protocols used postoperatively have been standar.dised.' In
contrast, the indications for and contraindications to liver
transplantation continue to be modified. Large numbers of
patients have undergone liver transplantation in recent years
and analyses of large series of patients have made it
possible to determine more accurately the outcome of liver
transplantation in specific hepatic disease processes. As a
result, subsets of patients who are more likely to survive
long term have been identified. This is particularly true of
patients with viral hepatitis.
Hepatitis B
Liver transplantation in HBsAg-positive patients remains
controversial.' For many years a carrier state of HBsAg was
regarded as a contraindication to transplantation.' After
transplantation patients with hepatitis B are at high risk of
becoming reinfected with the virus which caused the original
disease, and once reinfection occurs it almost invariably
leads to chronicity and recurrence of the chronic active
hepatitis.' Thus patients who are HBsAg positive have a
significantly worse prognosis after transplantation than
patients who are HBsAg negative.'
The ethical dilemma is compounded by the magnitude of
the epidemiological problem. In HBV endemic areas, such
as southern Africa, HBsAg-positive patients constitute a
large, if not the largest, proportion of disorders causing end-
stage liver disease. Exclusion of patients who are HBsAg-
positive from transplant waiting lists would deprive many
young patients, who are in the most productive years of life
and otherwise ideal transplant candidates, from the only
option available to them. Thus identification of subsets of
patients with hepatitis B who have a better outcome or the
introduction of measures to improve the outcome after liver
transplantation would have important implications locally.
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